A practical reference on certificate of analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-06 and is reviewed periodically as new material appears.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
The drug is a controlled substance in many countries, so non-medical use for purposes such as improving physique and performance has been generally illicit. In the United States, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee unanimously concluded in 1984 that there was no evidence of efficacy for oxandrolone. On March 26, 2019, Gemini asked FDA to withdraw approval for all doses of the drug, stating that they were no longer marketing it. FDA notified Gemini and other license holders on December 16, 2022, that it believed that the potential problems with the drug that the drug were sufficiently serious that it should be removed from the market, citing the 1984 finding of lack of efficacy and the extensive safety warnings and precautions listed on the prescribing information, "including peliosis hepatis, sometimes associated with liver failure and intra-abdominal hemorrhage; liver cell tumors, sometimes fatal; and blood lipid changes that are known to be associated with increased risk of atherosclerosis" as well as "cholestatic hepatitis, hypercalcemia in patients with breast cancer, and increased risk for the development of prostatic hypertrophy and prostatic carcinoma in geriatric patients." Gemini and Sandoz requested that the FDA completely withdraw approval for the drug.
=== App privacy violation === On June 1, 2022, the federal privacy commissioner, with officials in Quebec, British Columbia and Alberta, announced the results of its investigation, that Tim Hortons violated privacy laws by tracking people who used its app, gathering their location data hundreds of times a day – even when the app was not in use. As way of restitution, Tim Hortons offered eligible app users a free coffee and a baked good.
On November 27, The Washington Post published an article alleging that Secretary of Defense Pete Hegseth had ordered the officers responsible for the first airstrike on September 2, 2025, to "kill everyone" on board, prompting Admiral Frank M. Bradley to order a second strike to kill the two survivors of the initial strike, who were clinging to the wreckage of the boat that had been by the initial strike. As no quarter orders are forbidden under the Law of war, the second September 2 strike was widely criticized as constituting a war crime even under the Trump Administration's justification for the boat strike campaign in general, with the chair of the United States Senate Committee on Armed Services, Republican Senator Roger Wicker, along with ranking member Jack Reed, promising "vigorous oversight to determine the facts related to these circumstances". According to The New York Times, five U.S. officials stated that while Hegseth did, on September 2, order the killing of all individuals aboard the alleged drug boat, he did not specifically address what was to be done if any individuals survived the initial strike and was not present when Bradley carried out the second strike. After Hegseth refused to release a video of the second strike to Congress, the United States Senate placed a provision in the 2026 National Defense Authorization Act holding back a quarter of Hegseth's travel budget until he showed the video to lawmakers.
=== Nonsurgical === Prevention of movement between the layers allows the tentative initial bond of fibrin to be reinforced by wound healing with a thin, strong, layer of scar. Avoiding certain positions for certain surgeries may have an effect. (In abdominoplasty, sitting upright with the knees bent and hips flexed will cause pressure across the lower abdomen and a tendency to seroma formation. The patient is best to stand or at least be semirecumbent). External pressure may help in immobilization, but also is thought to reduce the tendency of the fluid to leak out of vessels by increasing the backpressure on those fluid sources. Following breast augmentation or double mastectomy, binding the chest may be recommended for several weeks to minimize the risk of seromas.
Sources: en.wikipedia.org
== Methods == Several methods for cell lysis exist, sometimes used in combination. Examples include liquid homogenization, freeze thawing, and physical disruption such as sonication, or the use of hypotonic solutions that cause osmotic swelling and eventual bursting of the cell.
The smelling organs of the terrestrial coconut crab are similar to those of insects. In an odd cross-phyla example, an insect, the hummingbird hawk-moth (Macroglossum stellatarum), also feeds by hovering in front of flowers and drinking their nectar in the same way as hummingbirds and sunbirds. Pill bugs and pill millipedes have evolved near-identical defensive plates, even being difficult to tell apart at a glance. The giant isopod also provides a large, deep-sea equivalent. Silk: spiders, silk moths, larval caddis flies, and the weaver ant all produce silken threads. The praying mantis body type – raptorial forelimb, prehensile neck, and extraordinary snatching speed - has evolved not only in mantises but also independently in neuropteran insects Mantispidae. Gripping limb ends have evolved separately in scorpions and in some decapod crustaceans, like lobsters and crabs. These chelae or claws have a similar architecture: the next-to-last segment grows a projection that fits against the last segment. Agriculture: some kinds of ants, termites, and ambrosia beetles have for a long time cultivated and tend fungi for food. These insects sow, fertilize, and weed their crops. A damselfish also takes care of red algae carpets on its piece of reef; the damselfish actively weeds out invading species of algae by nipping out the newcomer. Slave-making behavior has evolved several times independently in the ant subfamilies Myrmicinae and Formicinae, and more than ten times in total in ants. Proleg: a fleshy leg on many larvae of insects has independently evolved in several orders.
=== Kl--Ku === Martin Heinrich Klaproth (1743–1817), German chemist, who discovered uranium and zirconium, and contributed to the discovery of other elements Trevor Kletz (1922–2013), British promoter of industrial safety Aaron Klug (1926–2018), winner of the 1982 Nobel Prize in Chemistry for developing crystallographic electron microscopy Emil Knoevenagel (1865–1921) German organic chemist, known for the condensation reaction of carbonyl compounds with active methylene compounds Jeremy Randall Knowles (1935–2008), British physical organic chemist known for studies of chemical mechanisms, especially in enzyme catalysis William Standish Knowles (1917–2012), 2001 Nobel Prize in Chemistry for work on asymmetric synthesis, specifically in hydrogenation reactions Walter Kohn (1923–2016), 1998 Nobel Prize in Chemistry for contributions to the understanding of the electronic properties of materials Adolph Wilhelm Hermann Kolbe (1818–1884), German chemist known for Kolbe nitrile synthesis Izaak Kolthoff (1894–1993), Dutch-American chemist with abundant published research in diverse fields of analysis, the "Father of Analytical Chemistry" Arthur Kornberg (1918–2007), American biochemist, Nobel Prize in Chemistry (1959) for discovery of DNA polymerase Hans Kornberg (1928–2019), British biochemist known for research in microbial biochemistry Roger D. Kornberg (born 1947), 2006 Nobel Prize in Chemistry for elucidation of how genetic information from DNA is copied to RNA Teresa Kowalska (1946–2023), Polish chemist, specialized in the theory and application of chromatography Hans A.
Lithium toxicity, which is also called "lithium overdose" or "lithium poisoning", is the condition of having too much lithium in the blood. This condition also happens in persons who are taking lithium in which the lithium levels are affected by drug interactions in the body. Lithium toxicity occurs at levels above 1.5 mmol/L. Lithium levels above 2.0 mmol/L can lead to disorientation, renal failure, seizures, and coma. Above 2.0 mmol/L, acute renal failure can occur, and kidney dialysis may be used. In the elderly, signs of toxicity can occur at half the levels of younger patients. In acute toxicity, people have primarily gastrointestinal symptoms such as vomiting and diarrhea, which may result in volume depletion. During acute toxicity, lithium distributes later into the central nervous system resulting in mild neurological symptoms, such as dizziness. In chronic toxicity, people have primarily neurological symptoms which include nystagmus, tremor, hyperreflexia, ataxia, and change in mental status. During chronic toxicity, the gastrointestinal symptoms seen in acute toxicity are less prominent. The symptoms are often vague and nonspecific. If the lithium toxicity is mild or moderate, lithium dosage is reduced or stopped entirely. If the toxicity is severe, lithium may need to be removed from the body.
=== Bernot et al. (2023) === In recent study, Bernot et al. placed Copepoda as a sister group to Branchiopoda in Allotriocarida, which result in the recovery of clade Communostraca. Multicrustacea was not found. There are some major changes within class Malacostraca.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.